Access

On this page, you’ll find information on how bamlanivimab is being distributed across the country and how to identify infusion sites of care in your state. Be sure to scroll down to our Access FAQs which also provide more information regarding the process to order product and reimbursement.

The federal government, in conjunction with state health departments, will allocate supply of bamlanivimab to individual sites of care across the United States proportionally based on confirmed COVID-19 cases. Sites that have been allocated product will be contacted by and can agree to accept shipments from AmerisourceBergen, a distributor. If you are a healthcare provider and have questions about whether or not your site of care has been allocated product, you may contact your state health department directly. A list of state health departments can be found here. If you cannot get ahold of your state health department, or have additional questions, please call our dedicated Lilly COVID Hotline at 1-855-545-5921.

If you have a question about enrolling a patient in a clinical trial, please visit our Lilly Trial Guide.

Find an infusion site near you

Some states are partnering with the National Infusion Center Association (NICA) to make it easier to identify infusion site locations by state. Click "Go" to be redirected to the COVID infusion therapy search tool, hosted by NICA.^* Please note that not all states are included and a site’s inclusion in this tool does not imply current availability of doses.

^*IMPORTANT INFORMATION: Infusion sites displayed in this tool have been authorized to administer antibody treatments for COVID-positive patients under Emergency Use Authorization. These antibody therapies are restricted to certain high-risk patients and require a drug order (similar to a prescription) from a Health Care Provider (HCP) for eligible patients. HCPs must verify eligibility of their patients and verify the availability of doses at an authorized infusion site before they refer an eligible patient to schedule an appointment to receive treatment at an authorized infusion site.

Frequently Asked Questions

FAQs regarding access to bamlanivimab

: The federal government, in conjunction with state health departments, will allocate supply of bamlanivimab to individual sites of care across the United States proportionally based on confirmed COVID-19 cases. Sites that have been allocated product will be contacted by and can agree to accept shipments from the distributor, AmerisourceBergen. If you are a healthcare provider and have questions about whether or not your site of care has been allocated product, you may contact your state health department directly. A list of state health department websites may be found: here. If you cannot get ahold of your state health department, or have additional questions, please call our dedicated Lilly COVID Hotline at 1-855-545-5921.

Through the federally-run allocation program, bamlanivimab will be purchased by the federal government and offered at no cost to states, sites of care, or patients. Services and ancillary expenses necessary to administer the infusion are the responsibility of the individual site of care and can be billed according to published Centers for Medicare & Medicaid Services (CMS) guidance found at www.cms.gov for Medicare patients. There you will find the specific code(s) for each COVID-19 monoclonal antibody product and specific administration code(s) for Medicare payment. The codes for bamlanivimab are included below for reference:

Q0239:

Long descriptor: Injection, bamlanivimab-xxxx, 700 mg
Short descriptor: bamlanivimab-xxxx

M0239:

Long Descriptor: intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
Short Descriptor: bamlanivimab-xxxx infusion

Commercial reimbursement is anticipated but may be variable based on the individual plan.

: If approved to receive bamlanivimab, a representative from AmerisourceBergen will reach out to you directly to let you know you have been approved to receive the allocated amount of product. When they reach out, they will provide you with information on how to receive product.

: Bamlanivimab is authorized for use for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Ultimately, it is up to the federal and state governments to determine where allocated product will be offered. If you have questions about whether your site of care has been chosen or if you would like to request future allocation, please contact your state health department directly.

: If you have been approved to receive allocation of product, AmerisourceBergen will reach out to you directly to confirm that you would like to receive the allocated amount of product. If you believe you have been approved to receive an allocation but have yet to be contacted please contact c19therapies@amerisourcebergen.com.

: The federal government will allocate cases of bamlanivimab to states, territories, and identified agencies on a weekly basis. You can view the most updated allocation tables here.

Clinical investigators, hospitals or clinical sites interested in participating in one of Lilly’s clinical trials for a potential COVID-19 treatment should call 1-877-CT-LILLY (1-877-285-4559) or email covid19potentialsite@lilly.com

Genuine bamlanivimab

Ensuring the authenticity of bamlanivimab

Eli Lilly and Company is committed to patient safety and ensuring that people have accurate information about investigational bamlanivimab, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate bamlanivimab to protect patients from products that might be dangerous and lead to serious and life-threatening harm.

Bamlanivimab is authorized in the United States for use under an EUA and can only be accessed through the request of a treating physician.

Bamlanivimab is only administered intravenously.

Bamlanivimab is not taken orally and is not available in a capsule or tablet form.

Authentic bamlanivimab, manufactured by Eli Lilly and Company, will include the Lilly name and logo on the label, and is dispensed in a vial with either a salmon or slate cap.

Bamlanivimab is not sold online.

The authenticity of products acquired outside of the legitimate supply chain cannot be verified by Eli Lilly and Company.

If you believe you have purchased or have been offered counterfeit bamlanivimab, please report it to the FDA.